Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

176.95 +5.22 (+3.04%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 11,328,624
Open 174.34
Bid (Size) 176.95 (2)
Ask (Size) 177.45 (1)
Prev. Close 171.73
Today's Range 173.50 - 178.86
52wk Range 137.65 - 207.32
Shares Outstanding N/A
Dividend Yield 3.50%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Stock Market Is Soaring but These 2 Stocks Are Still Dirt Cheap Buys
Via The Motley Fool
3 Dividend Stocks That Are Screaming Buys in November
Political uncertainty has created buying opportunities among blue-chip healthcare stocks with big-time dividends. 
Via The Motley Fool

Performance

YTD
+10.72%
+10.72%
1 Month
-6.70%
-6.70%
3 Month
-10.38%
-10.38%
6 Month
+13.91%
+13.91%
1 Year
+27.61%
+27.61%

More News

Read More
AbbVie Jumps Nearly 4% On An Upgrade Despite Bristol Myers-Tied Setback
Via Investor's Business Daily
This Elastic Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Via Benzinga
Unpacking the Latest Options Trading Trends in AbbVie
Via Benzinga
What To Do After The Worst Week For Healthcare Stocks Since March 2020?
Via Talk Markets
Where Will AbbVie Be in 5 Years?
Via The Motley Fool
Smart Money Is Betting Big In ABBV Options
Via Benzinga
Seeking Beta
Via Talk Markets
Why This Beaten-Down Dividend Stock Is a No-Brainer Buy on the Dip
Via The Motley Fool
Super Micro Computer, Moderna And XPeng Were Among Top 10 Large Cap Stocks Losing Big Last Week (November 11-15): Check Out Other Losers
Via Benzinga
AbbVie, Bitcoin And An Energy Stock On CNBC's 'Final Trades'
Via Benzinga
Got $1,500 to Invest? AbbVie Just Proved the Bull Thesis for Its Stock
Via The Motley Fool
Abbvie Stock Price Analysis – A Post-Humira Dip, New Drug Hopes, And Election Buzz – Is Now The Time To Buy?
Via Talk Markets
Navigating 14 Analyst Ratings For AbbVie
Via Benzinga
AbbVie Stock Drops 12% On Schizophrenia Drug Setback: Should You Buy The Dip?
Via Talk Markets
This Is What Whales Are Betting On AbbVie
Via Benzinga
Viking Fund Management Sells Big Oil Stocks In Q3, Cuts Tesla Position In Half, Adds To Largest Position Broadcom
Via Benzinga
2 Dividend Stocks to Buy Hand Over Fist in November
Via The Motley Fool
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio
Via Benzinga
Bristol-Myers Squibb's $14 Billion Potential - Analyst Upgrades Stock
Via Benzinga
Biotech Stocks Are Rallying: What Is Your Playbook?
Via Talk Markets
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why AbbVie Stock Was Getting Mashed on Monday
Via The Motley Fool
What's Going On With Bristol-Myers Squibb Shares Monday?
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.